Our mission is to research, develop, and deliver innovative medicines to improve and extend people’s lives with cancer.
MAIA Biotechnology, Inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Investigational drug candidates and research:
- THIO, a first-in-class telomere-by-telomerase targeting agent in clinical development for the treatment of multiple cancer types (read more about THIO)
- FKBP52 preclinical program is evaluating the FKBP52 co-chaperone as a therapeutic target for prostate cancer and breast cancer. Two compound families have been identified with a potentially novel mode of action targeting androgen receptor (AR) and direct FKBP52 co-chaperone inhibition, that are important in prostate and breast cancers (read more about FKBP52)